Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP-
dc.contributor.authorMARIA, Durvanei Augusto-
dc.contributor.authorSOUZA, Jean Gabriel de-
dc.contributor.authorMORAIS, Katia L. P.-
dc.contributor.authorBERRA, Carolina Maria-
dc.contributor.authorZAMPOLLI, Hamilton de Campos-
dc.contributor.authorDEMASI, Marilene-
dc.contributor.authorSIMONS, Simone Michaela-
dc.contributor.authorSAITO, Renata de Freitas-
dc.contributor.authorCHAMMAS, Roger-
dc.contributor.authorCHUDZINSKI-TAVASSI, Ana Marisa-
dc.identifier.citationINVESTIGATIONAL NEW DRUGS, v.31, n.3, p.493-505, 2013-
dc.description.abstractIn cancer-treatment, potentially therapeutic drugs trigger their effects through apoptotic mechanisms. Generally, cell response is manifested by Bcl-2 family protein regulation, the impairment of mitochondrial functions, and ROS production. Notwithstanding, several drugs operate through proteasome inhibition, which, by inducing the accumulation and aggregation of misfolded or unfolded proteins, can lead to endoplasmic reticulum (ER) stress. Accordingly, it was shown that Amblyomin-X, a Kunitz-type inhibitor identified in the transcriptome of the Amblyomma cajennense tick by ESTs sequence analysis of a cDNA library, obtained in recombinant protein form, induces apoptosis in murine renal adenocarcinoma (RENCA) cells by: inducing imbalance between pro- and anti-apoptotic Bcl-2 family proteins, dysfunction/mitochondrial damage, production of reactive oxygen species (ROS), caspase cascade activation, and proteasome inhibition, all ER-stress inductive. Moreover, there was no manifest action on normal mouse-fibroblast cells (NHI3T3), suggesting an Amblyomin-X tumor-cell selectivity. Taken together, these evidences indicate that Amblyomin-X could be a promising candidate for cancer therapy.-
dc.description.sponsorshipFundacao de Amparo a Pesquisa do Estado de Sao Paulo [FAPESP 2010/52669-3, CAT/CEPID - 1998/14307-9]-
dc.description.sponsorshipUniao Quimica Farmaceutica Nacional-
dc.description.sponsorshipConselho Nacional de Pesquisa e Desenvolvimento (CNPq, INCTTox)-
dc.description.sponsorshipCoordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)-
dc.relation.ispartofInvestigational New Drugs-
dc.subjectBcl-2 family protein-
dc.subjectReactive oxygen species-
dc.subject.otherendoplasmic-reticulum stress-
dc.subject.otherbcl-2 family proteins-
dc.subject.othermembrane permeabilization-
dc.subject.othermediated apoptosis-
dc.subject.otheroxidative stress-
dc.titleA novel proteasome inhibitor acting in mitochondrial dysfunction, ER stress and ROS production-
dc.rights.holderCopyright SPRINGER-
dc.subject.wosPharmacology & Pharmacy-
dc.type.categoryoriginal article-
dc.type.versionpublishedVersion-, Durvanei Augusto:Inst Butantan, Lab Bioquim & Biofis, BR-05503900 Sao Paulo, Brazil-, Jean Gabriel de:Inst Butantan, Lab Bioquim & Biofis, BR-05503900 Sao Paulo, Brazil; Univ Fed Sao Paulo, Dept Bioquim, Sao Paulo, Brazil-, Katia L. P.:Inst Butantan, Lab Bioquim & Biofis, BR-05503900 Sao Paulo, Brazil; Univ Fed Sao Paulo, Dept Bioquim, Sao Paulo, Brazil-, Carolina Maria:Inst Butantan, Lab Bioquim & Biofis, BR-05503900 Sao Paulo, Brazil-, Hamilton de Campos:Inst Butantan, Lab Bioquim & Biofis, BR-05503900 Sao Paulo, Brazil; Inst Butantan, Programa Posgrad Interunidades Biotecnol, USP, IPT, BR-05503900 Sao Paulo, Brazil-, Marilene:Inst Butantan, Lab Bioquim & Biofis, BR-05503900 Sao Paulo, Brazil-, Simone Michaela:Inst Butantan, Lab Bioquim & Biofis, BR-05503900 Sao Paulo, Brazil-, Ana Marisa:Inst Butantan, Lab Bioquim & Biofis, BR-05503900 Sao Paulo, Brazil; Univ Fed Sao Paulo, Dept Bioquim, Sao Paulo, Brazil; Inst Butantan, Programa Posgrad Interunidades Biotecnol, USP, IPT, BR-05503900 Sao Paulo, Brazil-
hcfmusp.relation.referenceAkagi EM, 2012, BIOMED PHARMACOTHER, V66, P64, DOI 10.1016/j.biopha.2011.11.015-
hcfmusp.relation.referenceAzad N, 2010, ANN NY ACAD SCI, V1203, P1, DOI 10.1111/j.1749-6632.2010.05608.x-
hcfmusp.relation.referenceBakhshi J, 2008, APOPTOSIS, V13, P904, DOI 10.1007/s10495-008-0221-x-
hcfmusp.relation.referenceBatista IFC, 2010, ARCH BIOCHEM BIOPHYS, V493, P151, DOI 10.1016/
hcfmusp.relation.referenceBellini MH, 2008, J FLUORESC, V18, P1163, DOI 10.1007/s10895-008-0368-4-
hcfmusp.relation.referenceBiasutto L, 2010, MITOCHONDRION, V10, P670, DOI 10.1016/j.mito.2010.06.004-
hcfmusp.relation.referenceChipuk JE, 2004, SCIENCE, V303, P1010, DOI 10.1126/science.1092734-
hcfmusp.relation.referenceChudzinski-Tavassi AM, 2010, TOXICON, V56, P1145, DOI 10.1016/j.toxicon.2010.04.019-
hcfmusp.relation.referenceDenecker G, 2001, CELL DEATH DIFFER, V8, P829, DOI 10.1038/sj.cdd.4400883-
hcfmusp.relation.referenceDeniaud A, 2008, ONCOGENE, V27, P285, DOI 10.1038/sj.onc.1210638-
hcfmusp.relation.referenceDlamini Z, 2004, PHARMACOL THERAPEUT, V101, P1, DOI 10.1016/j.pharmthera.2003.08.005-
hcfmusp.relation.referenceDrexler HCA, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004161-
hcfmusp.relation.referenceEllgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052-
hcfmusp.relation.referenceFaitova J, 2006, CELL MOL BIOL LETT, V11, P488, DOI 10.2478/s11658-006-0040-4-
hcfmusp.relation.referenceFribley A, 2004, MOL CELL BIOL, V24, P9695, DOI 10.1128/MCB.24.22.9695-9704.2004-
hcfmusp.relation.referenceGermain Marc, 2003, Sci STKE, V2003, ppe10, DOI 10.1126/stke.2003.173.pe10-
hcfmusp.relation.referenceGriscavage J M, 1995, Adv Pharmacol, V34, P215-
hcfmusp.relation.referenceHanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013-
hcfmusp.relation.referenceHancock JT, 2001, BIOCHEM SOC T, V29, P345, DOI 10.1042/0300-5127:0290345-
hcfmusp.relation.referenceHaynes CM, 2004, MOL CELL, V15, P767, DOI 10.1016/j.molcel.2004.08.025-
hcfmusp.relation.referenceHikita H, 2010, HEPATOLOGY, V52, P1310, DOI 10.1002/hep.23836-
hcfmusp.relation.referenceJin SK, 2001, J CELL SCI, V114, P4139-
hcfmusp.relation.referenceKabore AF, 2004, CURR CANCER DRUG TAR, V4, P147, DOI 10.2174/1568009043481551-
hcfmusp.relation.referenceKim R, 2007, CANCER GENE THER, V14, P1, DOI 10.1038/sj.cgt.7700986-
hcfmusp.relation.referenceKing FW, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007283-
hcfmusp.relation.referenceKostova Z, 2003, EMBO J, V22, P2309, DOI 10.1093/emboj/cdg227-
hcfmusp.relation.referenceLameu C, 2010, CYTOM PART A, V77A, P220, DOI 10.1002/cyto.a.20860-
hcfmusp.relation.referenceLavrik IN, 2010, CURR OPIN BIOTECH, V21, P551, DOI 10.1016/j.copbio.2010.07.001-
hcfmusp.relation.referenceWei MC, 2000, GENE DEV, V14, P2060-
hcfmusp.relation.referenceLivak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262-
hcfmusp.relation.referenceMaddika S, 2007, DRUG RESIST UPDATE, V10, P13, DOI 10.1016/j.drup.2007.01.003-
hcfmusp.relation.referenceMarzetti E, 2008, FREE RADICAL BIO MED, V44, P160, DOI 10.1016/j.freeradbiomed.2007.05.028-
hcfmusp.relation.referenceMihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9-
hcfmusp.relation.referenceMimnaugh Edward G., 2004, Molecular Cancer Therapeutics, V3, P551-
hcfmusp.relation.referenceMURPHY GP, 1973, J NATL CANCER I, V50, P1013-
hcfmusp.relation.referenceNakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513-
hcfmusp.relation.referenceNawrocki ST, 2005, CANCER RES, V65, P11658, DOI 10.1158/0008-5472.CAN-05-2370-
hcfmusp.relation.referenceNawrocki ST, 2004, MOL CANCER THER, V3, P59-
hcfmusp.relation.referenceOltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579-
hcfmusp.relation.referenceOrrenius S, 2003, NAT REV MOL CELL BIO, V4, P552, DOI 10.1038/nrm1150-
hcfmusp.relation.referencePICK E, 1981, J IMMUNOL METHODS, V46, P211, DOI 10.1016/0022-1759(81)90138-1-
hcfmusp.relation.referenceRahmani M, 2007, MOL CELL BIOL, V27, P5499, DOI 10.1128/MCB.01080-06-
hcfmusp.relation.referenceRalph SJ, 2006, RECENT PAT ANTI-CANC, V1, P327, DOI 10.2174/157489206778776952-
hcfmusp.relation.referenceRocha FGD, 2011, J GENE MED, V13, P148, DOI 10.1002/jgm.1547-
hcfmusp.relation.referenceRutkowski DT, 2004, TRENDS CELL BIOL, V14, P20, DOI 10.1016/j.tcb.2003.11.001-
hcfmusp.relation.referenceSantos CXC, 2009, ANTIOXID REDOX SIGN, V11, P2409, DOI 10.1089/ARS.2009.2625-
hcfmusp.relation.referenceSchroder M, 2005, ANNU REV BIOCHEM, V74, P739, DOI 10.1146/annurev.biochem.73.011303.074134-
hcfmusp.relation.referenceScorrano L, 2003, SCIENCE, V300, P135, DOI 10.1126/science.1081208-
hcfmusp.relation.referenceShankar S, 2007, INT J ONCOL, V30, P905-
hcfmusp.relation.referenceSingh SV, 2005, J BIOL CHEM, V280, P19911, DOI 10.1074/jbc.M412443200-
hcfmusp.relation.referenceSlee EA, 2004, ONCOGENE, V23, P2809, DOI 10.1038/sj.onc.1207516-
hcfmusp.relation.referenceSoriano ME, 2010, ADV EXP MED BIOL, V687, P97-
hcfmusp.relation.referenceSy LK, 2008, CANCER RES, V68, P10229, DOI 10.1158/0008-5472.CAN-08-1983-
hcfmusp.relation.referenceTsai B, 2002, NAT REV MOL CELL BIO, V3, P246, DOI 10.1038/nrm780-
hcfmusp.relation.referenceTsutsui H, 2011, AM J PHYSIOL-HEART C, V301, pH2181, DOI 10.1152/ajpheart.00554.2011-
hcfmusp.relation.referenceVogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675-
hcfmusp.relation.referenceZong WX, 2003, J CELL BIOL, V162, P59, DOI 10.1083/jcb.200302084-
Appears in Collections:

Artigos e Materiais de Revistas Científicas - FM/MDR
Departamento de Radiologia - FM/MDR

Artigos e Materiais de Revistas Científicas - LIM/24
LIM/24 - Laboratório de Oncologia Experimental

Artigos e Materiais de Revistas Científicas - ODS/03
ODS/03 - Saúde e bem-estar

Files in This Item:
File Description SizeFormat 
  Restricted Access
publishedVersion (English)619.99 kBAdobe PDFView/Open Request a copy

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.